Primary Immunodeficiency Diseases Market worth US$7.5 bn by 2023, Newborn Screening in Emerging Markets to be Key Opportunity

Primary immunodeficiency disease (PIDD) comprises group of rare disorders, mostly genetic in nature, wherein a part of the immune system is missing or does not function correctly. The symptoms include a markedly increased vulnerability to serious illness and infection, organ damage and the immune system also attacking the body’s own tissues and cells. Primary Immunodeficiency is largely treated with therapies derived from human plasma, and in the most severe forms, replacement of stem cells. The report on global primary immunodeficiency diseases market by treatment has been studied and assessed for four prominent categories: Immunoglobulin Replacement Therapy, Antibiotic Therapy, Stem cells and gene therapy and others. The market for others provide a cumulative estimation for vaccines and nutritional supplement.

Browse Full Report With TOC:- http://www.transparencymarketresearch.com/primary-immunodeficiency-disease-market.html

Immunoglobulin (Ig) has been used to treat hypogammaglobulinaemia for more than two decades or more. Recently, it has also been used to treat diseases such as combined immunodeficiency and partial antibody deficiency. Ig are as a replacement therapy are usually administered via two prominent modes i.e. intravenous and subcutaneous which has well demonstrated their efficacy and safety in primary immunodeficiency (PIDD) treatment. A recent survey published by the Medical Insights Groups in 2014 illustrated that 54% of home-based Ig are delivered through SC, whereas only 46% are considered for IV in the U.S. Demand for SC is growing rapidly especially among school going children as it can be delivered in home settings with a one hour infusion, whereas venous access requires three to four hour infusion for IVIG.

Long-term prophylactic antibiotics are being widely implemented as primary or adjunctive therapy for PIDD treatment. This practice has transformed clinical outcomes in the setting of chronic granulomatous disease, complement deficiencies, Wiskott-Aldrich syndrome, hyper IgE syndrome. Patients with PIDD are often prescribed longer and stronger courses of antibiotics than usual. This could mean courses of 14 days or sometimes longer. The reason for this is to prevent relapse or recurrence of infection. Some of the commonly used antibiotics in PIDD treatment include penicillin, cephalosporins, macrolides, fluoroquinolones, sulfonamides, tetracyclines, and aminoglycosides.

Hematopoietic stem cell treatment (HSCT) successfully cures a wide range of primary immunodeficiency disorders. Advances in medical science has led to an improved survival rate and better quality of life, especially with respect to orphan diseases. HSCT owing to its better outcomes is now increasingly practiced for treating non-SCID based patients suffering from diseases such as Wiskott-Aldrich syndrome, Omenn syndrome, CD40 ligand deficiency and others. Gene therapy has been used to treat patients with SCID due to adenosine deaminase (ADA) deficiency, X-linked severe combined immunodeficiency, chronic granulomatous disease, and Wiskott-Aldrich syndrome. Various laboratories across the world are working at modifications of the viral vectors in order to improve their safety. Stem cells and gene therapy market is expected to be the fastest growing segment during the forecast tenure owing to increasing number of clinical trial and research studies and significant reduction in mortality and morbidity in past few years.

Lack of adequate nutrition can also lead to many illnesses including infections for which the individual with primary immunodeficiency disease is already at risk. Vitamin supplements include vitamins A, C, and E, which are all valuable parts of the body's defense system aid in increasing the production of healthy white blood cells and to fight infection.

The report offers a detailed description behind this high growth and outlines a possible growth trajectory for other segments of PIDD market such as by diseases, by test and by geography. The market study also profiled some of the leading companies operating in primary immunodeficiency diseases market across the globe. These encompasses Baxter International, Inc., Biotest AG, CSL Behring LLC, Bio Products Laboratory Ltd., Kedrion S.p.A., LFB S.A., Octapharma AG and Grifols S.A.

The global primary immunodeficiency diseases market is segmented into the following categories:
Global Primary Immunodeficiency Diseases Market, by Disease

Antibody Deficiency
Agammaglobulinaemia ((X-Linked and Autosomal Recessive)
Common Variable Immune Deficiency
Selective IgA Deficiency
IgG Subclass Deficiency
Others

Cellular Immunodeficiency
Ataxia Telangiectasia
Hyper IgM Syndromes
Wiskott-Aldrich Syndrome
DiGeorge Syndrome
Others

Innate Immune Disorders
Complement Deficiencies
Hyper IgE Syndrome
Others

Global Primary Immunodeficiency Diseases Market, by Test
Blood Test
Prenatal Testing

Global Primary Immunodeficiency Diseases Market, by Treatment
Immunoglobulin Replacement Therapy
Antibiotic Therapy
Stem cell and Gene Therapy
Others

Request For Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3137

About Us:-
Transparency Market Research (TMR) is a next-generation provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:-
Mr.Sudip.S
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
Email: sales@transparencymarketresearch.com

Read More

Could Cord Blood Banking be the Lifeline for Future Generations?

Several couples in recent years have realized the potential of umbilical cord blood, making cord blood banking a priority. By choosing to bank cord blood, parents not only open up the possibility of saving their child’s life if it is threatened by a disease, but also the life of a family member, relative, or a stranger. Cord blood refers to blood extracted from the umbilical cord and the placenta after the baby is born. The reason cord blood is stored in medical facilities across the world is that the blood cells it contains have the ability to renew themselves.

Browse Full Report: http://www.transparencymarketresearch.com/latam-cord-blood-banking-services-market.html

Rising Awareness about Cord Blood Banking Gives an Impetus to Blood Banking Services

As more and more parents are realizing the importance of saving cord blood, banking units that offer services such as collection and preservation are booming, especially in Latin American countries. The top players in the Latin America cord blood baking services market are Banco de Cordon Umbilical (BCU), Redcord S.A., America Cell Biobank, Inc., and CrioCenter. These banks are either private cord blood banking services or public cord blood banking services. Most of them are operating in countries such as Brazil, Colombia, Argentina, and Mexico. 

Growing Stem Cell Research Promotes Cord Blood Banking

Umbilical cord blood has a huge potential to be the source of progenitor cells that are usually used for the reconstitution of organs, tissues, and other functional areas. Today, cord blood transplantation is being used for treating a variety of diseases such a sarcoma, leukemia, lymphoma, and several other immune conditions and metabolic disorders. In the last twenty years, the stem cell therapeutics industry has also experienced a surge due to increasing investment and growing research and development.

Private Cord Blood Banking Services Toughen the Competition in the Market

The rise in technological and infrastructural development in Latin American countries has encouraged research into stem cell therapy, which has given cord blood banking a positive momentum. Most cord blood banking services in Latin America are being funded by governments. However, as private players are slowly making their way into the Latin American market, they are likely to make the scenario highly competitive for the existing players.

Browse Press Release: http://www.transparencymarketresearch.com/pressrelease/latam-cord-blood-banking-services-market.htm

In the coming years, countries in Latin America are expected to make a serious effort at reducing the limitation of public and private cord blood banking by executing a hybrid model. This model will entail the storage of cord blood for a dual purpose. One part of it will be used for the child or for the donor family, while the second portion will be used as a public donation. With the myriad possibilities that cord blood banking services offer and the remarkable progress in stem cell research, saving this blood could prove to be lifeline for future generations.

Download PDF Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=8413

About Us:-
Transparency Market Research (TMR) is a next-generation provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:-
Mr.Sudip.S
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
Email: sales@transparencymarketresearch.com

Read More

global allergy diagnostics market is poised to grow at the highest rate

Allergic reactions occur due to a hypersensitivity disorder of the immune system against certain substances present in the environment, which are often referred as allergens such as dust mites excretion, pollen, and pet dander. Allergic reactions have a detrimental impact on the human health causing significant morbidity due to otolaryngologic, pulmonary, and dermatologic disorders. According to an article published by the National Center for Biotechnology Information (NCBI), over 500 million people are suffering from allergic rhinitis globally.

Browse Full Report With TOC:- http://www.transparencymarketresearch.com/allergy-diagnostics-market.html

The morbidity pattern varies from chronic illnesses such as allergic rhinitis and allergic asthma to acute anaphylaxis from venom or medication. Allergies are observed to affect all age groups, races and ethnicity and economic classes, although, young children and elderly are at higher risk. Factors such as alarming rise in pollution and environmental toxicity, overcrowding due to population rise, lifestyle factors are leading to weakened immune systems and heightened vulnerability towards allergic reactions.

According to the World Allergy Organization, nearly 30% to 40% of the global population is affected by one or the other allergic conditions and currently no cure is available for these disorders. Consequently, there is a burgeoning global market for diagnostic services to detect allergies caused by different allergens. The positive test alone demonstrates sensitization but do not always indicate clinical reactivity. The complexity of the allergy diagnosis lies in the fact that the diagnosis does not rest entirely on test results but also needs to incorporate patient’s medical history and the genetic predisposition towards certain allergies. Accurate diagnosis and immunotherapy is the only ray of hope for seeking cure against most of the allergen sensitivities.

Some of the allergy diagnostic products and services include allergy markers, ImmunoCAP, recombinant gene technology, and EliA blood tests among others. Allergy diagnostics market is bound to grow in future owing to the current health scenario with parallel rise in demand for accurate diagnostic tools and services. To enable diagnosis and disease management of allergies and autoimmune disorders, allergens have been classified on the basis of product type and end-users:

The end-users segment includes healthcare institutions such as medical research centers, laboratories, hospitals, and health insurance companies. Product types can be further subdivided into:
Assay Kits and immunoassay analyzers
Instruments
Consumables
Luminometers

Immunoassay analyzers are expected to capture a huge share among the global allergy diagnostics market and is poised to grow at the highest rate. To map out the diagnostic allergy market on a global scale, North America accounts for the largest regional market followed by Europe and opening up newer avenues for the rapidly growing markets in Asia-Pacific. This trend is further backed by the statistical information from the European Academy of Allergy and Clinical Immunology (EAACI) which reported in 2012 that nearly 17 million Europeans have food allergies and there has been seven-fold rise in allergic reactions among children over the past decade. One in every thirteen children (under 18 years of age) in the U.S is exposed to this potentially serious condition. Consequently, the market has witnessed a remarkably high growth owing to the increasing awareness coupled with government initiatives for the unmet needs of the population in many countries. It is anticipated that the sector will experience a tremendous growth as a result of the demand side factors, investments in the products and services for detecting the allergic trigger.

Some of the key players contributing to this market segment are Allercheck Laboratories, Inc., bioMérieux SA, Danaher Corporation, Hitachi Chemical Diagnostics, Inc., HOB Biotech Group Co., Ltd., HYCOR BioMedical, Lincoln Diagnostics, Inc., Omega Diagnostics Group plc, Siemens Healthcare, Stallergenes, and Thermo Fisher Scientific, Inc.

Request For Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=5147

About Us:-
Transparency Market Research (TMR) is a next-generation provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:-
Mr.Sudip.S
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030

Read More

Spinal Muscular Atrophy (SMA) Market: Phase 3 Candidate ISIS-SMNRx to Reach US$0.47 bn by 2023

Spinal muscular atrophy is primarily a hereditary autosomal recessive disease that affects the nervous system areas that controls voluntary muscular movement. SMA is commonly identified as a genetic disorder causing mortality among people, especially infants. As per Orphanet, 1 infant out of 6,000 births is predicted to suffer spinal muscular atrophy. More than 10 mn individuals in the United States are carriers of spinal muscular atrophy. The spinal muscular atrophy market phase 3 candidate ISIS-SMNRx is predicted to reach US$0.47 bn by 2023.

Increasing Number of Infants with SMA to Drive Global Market

Recently, as per a news report, a few families in Morgantown found hope for their children who were suffering from spinal muscular atrophy. The families were denied access to the clinical trial drug SMNRx from ISIS Pharmaceuticals. Since then, the families, with the support of many others, have been trying to sign a petition to allow SMA-diagnosed children to have clear access to the relevant drugs for treatment.

Such and other events have occurred as the result of the growing prevalence of SMA among children. This will propel the global spinal muscular atrophy market in the coming years.

Browse Full Report: http://www.transparencymarketresearch.com/spinal-muscular-atrophy-market.html

Type 1 Spinal Muscular Atrophy to Lead Demand for Global SMA Market by 2023

Considering the increasing number of infants being diagnosed with spinal muscular atrophy, the spinal muscular atrophy market is expected to expand during the period from 2015 to 2023. On the basis of the symptoms and the age of onset, the SMA market is classified into Type 1 SMA, Type 2 SMA, Type 3 SMA, and Type 4 SMA. Type 1 spinal muscular atrophy is the most severe type and is found in infants aged up to six months. More than 60% of SMA cases are found to be Type 1 SMA, in which infants do not live for more than two years. Type 2 SMA affects children aged from six months to 18 months. Type 3 and 4 SMA are comparatively less severe and carry a prognosis of a normal lifespan. Physiotherapy is the best treatment suggested for SMA when it is at its early stage.

ISIS-SMNRx is an antisense medicine introduced by Isis Pharmaceutical and has shown positive results in clinical trials. Some other potential candidates are Olesoxime (TRO19622), RO6885247, scAAV9.CB.SMN, RG3039, LMI070, and CK-2127107. Phase 3 study of ISIS-SMNRx for treating Type 1 and Type 2 SMA is expected to be completed by 2016.

SMA is commonly diagnosed by recognizing mutation in the survival of motor neuron (SMN) gene. Muscle biopsy, nerve condition velocity, and electromyogram are some other ways by which SMA can be diagnosed. AveXis, Inc., F. Hoffmann-La Roche Ltd., Isis Pharmaceuticals, Inc., Cytokinetics, Inc., and Novartis AG are some of the prominent players in the spinal muscular atrophy market. 

Browse Press Release: http://www.transparencymarketresearch.com/pressrelease/spinal-muscular-atrophy-market.htm

At present, there is no well-defined cure for treating spinal muscular atrophy. ISIS-SMNRx is the only drug that is expected to be made available on large scale by 2017. The drug is expected to reach record sales of US$468.2 mn in the U.S. by 2023.

Read More

Spinal Muscular Atrophy Phase 3 Candidate ISIS-SMNRx Expected to Reach USD 0.47 Billion in Sales in the U.S

Spinal muscular atrophy (SMA) is a hereditary autosomal recessive disease affecting areas of the nervous system that control voluntary muscle movement. SMA is identified as a leading genetic disorder causing mortality among infants. According to Orphanet, one infant in 6,000 births is estimated to suffer from SMA. Furthermore, over 10 million people in the U.S. are carriers of SMA gene. Depending on the age of onset and symptoms, spinal muscular atrophy is classified in four main types. Type 1 SMA is the most severe form, and affects infants aged between zero and six months. Over 60% of annual SMA cases are of type 1 SMA, wherein infants usually do not survive for more than 2 years. Type 2 SMA is a moderate form affecting children aged between six months and eighteen months. Patients with Type 3 SMA and Type 4 SMA usually have a normal lifespan.

Currently, no cure exists for spinal muscular atrophy, and treatment is directed towards managing common symptoms of SMA. Physiotherapy is strongly recommended in early stages of the disease to extend range of motion and improve muscle flexibility. Other treatment methods are targeted to treat gastrointestinal and respiratory disorders, which are common in SMA patients. The SMA pipeline is dry, with single drug in phase 3, three in phase 2, and one in phase 3 clinical trials. ISIS-SMNRx by Isis Pharmaceutical is an antisense drug that has shown promising results in phase 2 clinical trials. Phase 3 study of ISIS-SMNRx for treatment of Type 1 SMA and Type 2 SMA is expected to complete in 2016. In the United States, the drug is expected to reach annual sales of USD 0.47 billion by 2023. Olesoxime (TRO19622) has completed its phase2/3 trials, and has shown promising results, with potential to effectively treat type 2 and type 3 SMA. Other potential candidates include Olesoxime (TRO19622), LMI070, RO6885247, CK-2127107, scAAV9.CB.SMN and RG3039.

The United States and Europe have higher percentage of diagnosed cases of SMA. Government and private organization in these regions are also involved in creating awareness about the disease. Higher confirmed carrier population would also help in faster market growth in these regions. Furthermore, government incentives for development of therapeutic alternatives for rare diseases also boosts research and development in the SMA landscape.Companies with potential candidates in the spinal muscular atrophy pipeline include AveXis, Inc., Cytokinetics, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, and Isis Pharmaceuticals, Inc.   

Spinal Muscular Atrophy Pipeline is segmented as below:
Late Stage Candidates (Phase 3)
ISIS-SMN Rx

Early Stage Candidates (Phase 1 and Phase 2)
Olesoxime (TRO19622)
LMI070
RO6885247
CK-2127107
CB.SMN
RG3039

Request For Sample Report:- http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7187

Read More

Chronic Stable Angina Market Upcoming Trends Analysis By 2019

Angina is a kind of chest pain or discomfort caused by poor flow of blood in the heart. This often occurs due to narrowing of blood arteries (atherosclerosis) caused by plaque formation or blood clot. People with obesity, history of heart disease, diabetes, high level of blood cholesterol and smoking are high risk of getting affected with angina. Some common symptoms associated with angina include pain, pressure or strange feeling in chest, shortness of breath, lightheadedness, irregular heartbeat, nausea or vomiting and weakness. Angina may be of two types: stable angina and unstable angina. Stable angina is the most common type of angina and is characterized by predictable pattern of chest pain. On the other hand, unstable angina has no typical pattern of chest pain. Stable angina happens when the heart does not get enough oxygen to perform a work which has been asked to do such as exercise or lifting heavy weight which may also occur due to cold weather and emotional stress.

Request For Brochure:- http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2214

Diagnosis of chronic stable angina includes medical history examination by a doctor and few tests such as coronary angiography, coronary risk profile (special blood tests), ECG, exercise tolerance test (stress test or treadmill test), stress echocardiogram and nuclear medicine (thallium) stress test. The treatment options for chronic stable angina include lifestyle changes such as daily exercise and quitting smoking, medications, and procedures such as angioplasty and stent placement and sometimes heart bypass surgery. Most commonly used medications include nitrates, ACE inhibitors and calcium channel blockers. Nicorandil, ranolazine and ivabradine are some of the latest anti-anginal agents which are also used for treating chronic stable angina.

The global market for chronic stable angina therapeutics is expected to grow at a moderate CAGR. Some major factors driving the market growth include high prevalence of the disease, extensive research and development of new more effective molecules. According to National Institute for Health and Clinical Excellence, an estimated 2 million people suffered from with stable angina in England in 2010. American Heart Association claims that around 9.1 million people are living with stable angina in the United States. Since stable angina cannot be cured immediately, it is expected that the base population of affected people will increase over the years and such high prevalence will drive market growth particularly in developed countries. The market for chronic stable angina therapeutics is likely to face significant challenges owing to patent expiry of major drugs such as bivalirudin (Angiomax/Angiox) in 2015 in Europe and rosuvastatin (Crestor) in 2016. These patent expiries are expected to attract generic manufacturers who will intensify the competition by selling drugs at low prices.

Geographically, North America represents the largest market, followed by Europe, Asia-Pacific and Rest of the World. In Asia-Pacific, rapid urbanization leading to life style changes and emerging economy of key countries such as India and China are expected to drive the market growth. Obesity, stress and cardiovascular diseases have become very common and will drive the market in developing countries significantly. Rapidly evolving medical tourism industry will also play a key role in driving the market growth in the region as a large number of people come from foreign countries to countries like India, Indonesia, Thailand and Singapore for the treatment of chronic stable angina.

There are many pharmaceutical companies and research institutes which are engaged in the development, manufacturing and marketing of drugs for treating chronic stable angina. Some major companies and research institutes include Pfizer, Inc., Mylan, Inc., Actavis Inc., Chong Kun Dang Pharmaceutical Corp., Roxane Laboratories, Inc., Gilead Sciences, Inc., CNS, Inc., Nanjing University and King's College London.

Browse Full Report With TOC:- http://www.transparencymarketresearch.com/chronic-stable-angina-therapeutics-market.html

This research report analyzes this market depending on its market segments, major geographies, and current market trends.
Geographies analyzed under this research report include
North America
Asia Pacific
Europe
Rest of the World 

This report provides comprehensive analysis of
Market growth drivers
Factors limiting market growth
Current market trends
Market structure
Market projections for upcoming years

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

About Us:-
Transparency Market Research (TMR) is a next-generation provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:-
Mr. Nachiket
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030

Read More

Nanocapsules Market Segment Forecasts up to 2023

Nanocapsules are drug delivery agents within the size range of 10nm to 1000 nm that are normally composed of a capsule shell and a hollow space in which desired substance or drug molecules are embedded. The ultrafine size of nanocapsules match the biological composition of human body such as RBCs which permits enhanced permeation and retention (EPR) through narrow channels during diffusion. Due to this EPR effect, nanocapsules are used as drug carriers. Nanocapsules can be formulation using various methods such as loading of drug molecules into hollow polyelectrolyte shell and another method being electrostatic layer by layer (LbL) technique. These latest LbL self-assembled polyelectrolyte capsules provide an efficient way to perform multiple drug delivery tasks simultaneously. Some nanocapsules are used for targeted drug delivery in anti-tumor and anti-tuberculosis therapies wherein the outer sphere of nanocapsules is fabricated by the lithography technique. Lipid nanocapsules (DNA LNCs) and multimodular systems (DNA MMS) are used in gene therapy.

Browse Full Report With TOC:- http://www.transparencymarketresearch.com/nanocapsules-market.html

Global investment in nanotechnology research has witnessed a six fold increase during the last decade. Consequently, nanotechnology will completely revolutionize the industrial processes in the near future due to its remarkable economic potential. Some of the key drivers for the market growth include investments and breakthroughs in biomedical, pharmaceutical, electronics, molecular and diagnostic fields. Besides, these nanocapsules are being increasingly used in agrochemicals, environment and wastewater treatments, genetic engineering, consumer goods and cosmetic procedures. Some of the most advanced future applications would be nanocapsule dressings to deliver antibiotics aiding faster wound healing without invasion to the skin. These nanocapsule bandages would be consistently demanded by defence and protection forces as they need not be changed periodically. According to the experts, electronics and magnetic sector will be the largest potential market for nanocapsules, followed by biopharmaceutical industry, catalysis, energy and engineering. However, growth in the nanocapsules market will also pose new challenges with respect to the toxicity and environmental impact of nanocapsules. Recently efforts have been made to overcome these drawbacks by developing eco-friendly versatile nanocapsules. For instance, nanocapsules introduced by the Center for Self-assembly and Complexity, Institute for Basic Science (IBS). Other factors such as cost escalation and consequences on the global economy especially in cases of under-developed economies with poor R&D investment would exhibit low social and ethical acceptance of nanocapsules.

Funding for nanotechnology is soaring worldwide at a competitive level, with each major economic power and many developed economies making a substantial investment to revamp their industrial and postindustrial supply chains. Technological inventions and discoveries in nanotechnology would cause tremendous growth in the global nanocapsule market. Due to a variety of potential applications, nanotechnology is expected to become the key technology in the near future. U.S. has invested around USD 3.7 billion through its National Nanotechnology Initiative for research activities. The European Union had spent approximately USD 1.2 billion and Japan USD 750 million by 2012. Moreover, there is a steady demand for medically advanced procedures in developed as well as developing regions having a well-established healthcare infrastructure. In the Asia Pacific region, the demand for nanocapsules is projected to rise owing to the high disease burden of tuberculosis and cancer. Some of the key factors that are likely to contribute toward the market growth are growing awareness about genetic counselling, genetic disorders, high prevalence of tuberculosis and multi-drug resistant tuberculosis, increasing trend in cancer and tumor ailments and surging demand for oncological treatments.

Presently, nanocapsules are under different stages of clinical trial phases facing several hurdles to gain market entry. However, few commercially available nanocapsules which are now commercially used as several pigments in sunscreen, scratch resistance coatings, catalysts, and biomarkers. Some of the key market players for these commercially available nanocapsules are Abraxis, Artificial Cell Technologies, Inc., BioDelivery Sciences International, Inc., Biophan Technologies, Inc., Cornerstone Pharmaceuticals, Inc., Genetic Immunity, Inc., Keystone Nano, Inc., Makefield Therapeutics, Inc., Nanospectra Biosciences, Inc., and Mersana Therapeutics, Inc.

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. This report provides comprehensive analysis of
Market growth drivers
Factors limiting market growth
Current market trends
Market structure
Market projections for upcoming years

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Reasons for Buying this Report:-

• This report provides pin-point analysis for changing competitive dynamics
• It provides a forward looking perspective on different factors driving or restraining market growth
• It provides a six-year forecast assessed on the basis of how the market is predicted to grow
• It helps in understanding the key product segments and their future
• It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
• It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
• It provides distinctive graphics and exemplified SWOT analysis of major market segments

Get Sample Report:- http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=5321

About Us:-
Transparency Market Research (TMR) is a next-generation provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:-
Mr.Nachiket
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

Read More